Trutect gives veterinarians a targeted option for canine parvo

Canine parvovirus care is shifting from supportive care alone to targeted therapy. Elanco’s canine parvovirus monoclonal antibody, now branded Trutect, received full USDA approval on December 15, 2025, after first being conditionally licensed in May 2023. The label had already expanded in June 2025 to include passive immunity for puppies exposed to parvovirus, adding a prophylactic use alongside treatment of infected dogs. USDA product records list the licensed product as anivovetmab for canine use under the trade name Trutect. Elanco says real-world use showed a 93% survival rate in treated puppies and an average 1.87-day reduction in hospitalization. (elanco.com)

Why it matters: For veterinary teams, this is one of the clearest examples of a long-feared infectious disease moving into the monoclonal antibody era. Parvo has historically been managed with aggressive fluids, antiemetics, antibiotics when indicated, analgesia, nutritional support, and isolation, with no virus-specific treatment. It remains especially dangerous because it attacks rapidly dividing cells in the intestinal lining and bone marrow, driving severe diarrhea, dehydration, leukopenia, and sepsis risk if untreated. Early data suggest the antibody may shorten hospitalization and reduce isolation time, which could ease bed pressure, staff workload, and cost conversations with pet parents, especially in ER, GP, and shelter settings. A retrospective shelter study from Ohio State and Gigi’s found dogs receiving standard of care plus the monoclonal antibody had shorter median hospitalization than standard care alone, though survival was similar in that cohort. (mspca.org; fearfreepets.com)

What to watch: Watch for broader protocol adoption, more independent field data, and practical guidance on timing, exposed-puppy use, and vaccine scheduling after passive-immunity dosing. That question matters because passive antibodies can interfere with modified-live parvovirus vaccination, much like maternally derived antibodies already do in young puppies and one reason booster timing remains so important. (pubmed.ncbi.nlm.nih.gov; fearfreepets.com)